Bolt Biotherapeutics, Inc. - Common Stock (NQ:BOLT)

0.3035 -0.0020 (-0.65%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jun 3, 2025 Add to My Watchlist

Price and Volume

Volume	108,060
Open	0.3000
Bid (Size)	0.3000 (3)
Ask (Size)	0.3035 (4)
Prev. Close	0.3055
Today's Range	0.3000 - 0.3100
52wk Range	0.2895 - 0.8000
Shares Outstanding	8,709,974
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025

From Bolt Biotherapeutics, Inc.

Via GlobeNewswire

Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates

May 08, 2025

From Bolt Biotherapeutics, Inc.

Via GlobeNewswire

Performance

YTD	-46.8%	-46.8%
1 Month	-18.0%	-18.0%
3 Month	-37.6%	-37.6%
6 Month	-49.4%	-49.4%
1 Year	-60.1%	-60.1%

More News

Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025

April 30, 2025

From Bolt Biotherapeutics, Inc.

Via GlobeNewswire

Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

April 25, 2025

From Bolt Biotherapeutics, Inc.

Via GlobeNewswire

Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

March 25, 2025

From Bolt Biotherapeutics, Inc.

Via GlobeNewswire

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

March 24, 2025

From Bolt Biotherapeutics, Inc.

Via GlobeNewswire

Bolt Biotherapeutics to Participate in Upcoming March Conferences

February 25, 2025

From Bolt Biotherapeutics, Inc.

Via GlobeNewswire

Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc.

February 11, 2025

From Bolt Biotherapeutics, Inc.

Via GlobeNewswire

Bolt Biotherapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

November 12, 2024

From Bolt Biotherapeutics, Inc.

Via GlobeNewswire

Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting

November 07, 2024

From Bolt Biotherapeutics, Inc.

Via GlobeNewswire

Bolt Biotherapeutics Announces Changes to its Board of Directors

September 04, 2024

From Bolt Biotherapeutics, Inc.

Via GlobeNewswire

BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

September 03, 2024

From The Schall Law Firm

Via Business Wire

BOLT Deadline: Rosen Law Firm Urges Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

September 02, 2024

From Rosen Law Firm

Via Business Wire

BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

September 02, 2024

From Schall Law

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CVS, Walgreens, SeaStar, and Bolt and Encourages Investors to Contact the Firm

August 30, 2024

From Bragar Eagel & Squire

Via GlobeNewswire

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt

August 29, 2024

From Faruqi & Faruqi LLP

Via GlobeNewswire

Bolt Biotherapeutics to Participate in Upcoming September Conferences

August 28, 2024

From Bolt Biotherapeutics, Inc.

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CVS, Walgreens, SeaStar, and Bolt and Encourages Investors to Contact the Firm

August 26, 2024

From Bragar Eagel & Squire

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CVS, FutureFuel, SeaStar, and Bolt and Encourages Investors to Contact the Firm

August 20, 2024

From Bragar Eagel & Squire

Via GlobeNewswire

BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

August 20, 2024

From Schall Law

Via GlobeNewswire

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Bolt Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BOLT

August 17, 2024

From The Rosen Law Firm PA

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against NIKE, FutureFuel, SeaStar, and Bolt and Encourages Investors to Contact the Firm

August 16, 2024

From Bragar Eagel & Squire

Via GlobeNewswire

BOLT Stock Earnings: Bolt Biotherapeutics Misses EPS, Beats Revenue for Q2 2024

August 13, 2024

Via InvestorPlace

Bolt Biotherapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

August 13, 2024

From Bolt Biotherapeutics, Inc.

Via GlobeNewswire

BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

August 13, 2024

From Schall Law

Via GlobeNewswire

Frequently Asked Questions

Is Bolt Biotherapeutics, Inc. - Common Stock publicly traded?

Yes, Bolt Biotherapeutics, Inc. - Common Stock is publicly traded.

What exchange does Bolt Biotherapeutics, Inc. - Common Stock trade on?

Bolt Biotherapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Bolt Biotherapeutics, Inc. - Common Stock?

The ticker symbol for Bolt Biotherapeutics, Inc. - Common Stock is BOLT on the Nasdaq Stock Market

What is the current price of Bolt Biotherapeutics, Inc. - Common Stock?

The current price of Bolt Biotherapeutics, Inc. - Common Stock is 0.3035

When was Bolt Biotherapeutics, Inc. - Common Stock last traded?

The last trade of Bolt Biotherapeutics, Inc. - Common Stock was at 06/03/25 04:00 PM ET

What is the market capitalization of Bolt Biotherapeutics, Inc. - Common Stock?

The market capitalization of Bolt Biotherapeutics, Inc. - Common Stock is 2.64M

How many shares of Bolt Biotherapeutics, Inc. - Common Stock are outstanding?

Bolt Biotherapeutics, Inc. - Common Stock has 3M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.